Group 1 - The core viewpoint of the article is that Rendu Biotech announced its mid-year profit distribution plan for 2025, which includes a cash dividend of 0.15 yuan per share (tax included) [1] - The record date for the dividend is set for November 25, 2025, while the ex-dividend date and the date of cash dividend distribution are both scheduled for November 26, 2025 [1]

中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁 度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在 科创板上市的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证 券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引第 7 号——回 购股份》等法律法规要求，对公司 2025 年中期利润分配所涉及的差异化分红进行了核 查，具体情况如下： 中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 差异化分红事项的核查意见 公司已于 2024 年 2 月 18 日召开第二届董事会第三次会议，审议通过了《关于以集 中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金不低于人民币 2,500 万元（含）且不超过人民币 5,000 万元（含），以集中竞价交易方式回购公司股份，回 购价格不超过人民币 53.31 元/股（含），本次回购股份将用于员工持股计划或股权激励。 回购期限为自公司董事会审议通过回购方案之日起不超过 6 个月。 一、本次差异化分红的原因 截至 2024 年 8 月 16 日，公司本次回购计划已实施完毕，已实际回购公 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-050 上海仁度生物科技股份有限公司 2025年中期权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/11/25 | 2025/11/26 | 2025/11/26 | 一、 通过分配方案的决策程序 3. 差异化分红送转方案： （1）本次差异化分红送转方案根据公司 2024 年年度股东大会审议通过的《关 于提请股东大会授权董事会决定 2025 年中期利润分配的议案》及第二届董事会第 十四次会议审议通过的《关于公司 2025 年度中期利润分配预案的议案》，公司向 实施权益分派股权登记日登记的总股本扣减公司回购专用证券账户中的股份为基 数，每股派发现金红利 0.15 元（含税）。如在实施权益分派的股权登记日前因股份 回购等事项导致公司可参与分配股本发生变动的，维持每股分配比例不变，相应 调整现金分红总额。本次利润分配以权益分 ...

Summary of Key Points Core Viewpoint - RenDu Bio (688193.SH) announced a cash dividend distribution for the first half of 2025, indicating a commitment to returning value to shareholders through cash dividends [1] Group 1: Dividend Distribution Details - The total share capital of the company is 40.0699 million shares, from which 1.2914 million shares held in the repurchase account will not participate in the profit distribution [1] - A cash dividend of 0.15 yuan per share will be distributed to all A-share shareholders, totaling 5.8168 million yuan (including tax) [1] - The record date for the dividend distribution is set for November 25, 2025, with the ex-dividend date on November 26, 2025 [1]

Group 1 - The company RenDu Bio (688193.SH) announced a cash dividend distribution for the first half of 2025, with a total of 4,006.99 million shares outstanding, excluding 1.29 million shares in the repurchase account [1] - Each A-share shareholder will receive a cash dividend of 0.15 yuan per share, totaling 5.82 million yuan (including tax) [1] - The record date for the dividend distribution is set for November 25, 2025, and the ex-dividend date is November 26, 2025 [1]

Industry Overview - The vaccine industry is experiencing a structural opportunity due to the rising trend of influenza, with a focus on flu vaccine developments [2][4] - Recent approvals for clinical trials include various vaccines from companies like Zhifei Biological, including a pertussis-diphtheria-tetanus vaccine and an mRNA shingles vaccine [2][4] - The National Influenza Center reported an increase in flu activity, with a total of 621 reported influenza-like illness outbreaks across the country [4] Market Performance - The vaccine sector saw a 3% increase, with the overall pharmaceutical and biological sector rising by 3.29% during the week of November 9-15, 2025 [5] - Notable companies in the vaccine sector that performed well include Jindike, Hualan Biological, and Baike Biological, while companies like Wantai Biological and Zhifei Biological lagged [6] Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio (ttm) was 101.87X, reflecting a 2.8X increase week-over-week, while the price-to-book (PB) ratio was 1.99X, up by 0.05X [7][8] Investment Insights - The vaccine industry is under pressure, with a notable structural differentiation among companies. The focus is on innovation and international expansion as key strategies for long-term growth [9] - The industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition causing short-term challenges [9] - Key drivers for the industry's long-term growth include policy support, demand increase due to an aging population, and technological advancements [10] Recommendations - Companies with strong research and development capabilities and differentiated product offerings, such as CanSino and Kanghua Biological, are recommended for investment [10] - Short-term focus should be on companies involved in flu vaccines due to the seasonal increase in demand [10]

Group 1 - The core point of the news is that Rendu Biotech experienced a decline in stock price and trading volume, with significant changes in financing and shareholder metrics [1][2]. - On November 17, Rendu Biotech's stock fell by 2.83%, with a trading volume of 37.01 million yuan. The financing buy-in was 2.76 million yuan, while the financing repayment was 3.78 million yuan, resulting in a net financing buy-in of -1.03 million yuan [1]. - As of November 17, the total financing and securities lending balance for Rendu Biotech was 30.17 million yuan, which represents 1.49% of its market capitalization and is above the 90th percentile of the past year [1]. Group 2 - As of September 30, Rendu Biotech had 3,765 shareholders, an increase of 7.73% from the previous period, with an average of 10,642 circulating shares per shareholder, up by 17.83% [2]. - For the period from January to September 2025, Rendu Biotech reported operating revenue of 119 million yuan, a year-on-year decrease of 8.79%, while the net profit attributable to shareholders increased by 50.15% to 7.01 million yuan [2]. - Since its A-share listing, Rendu Biotech has distributed a total of 20.58 million yuan in dividends [3].

证券代码：688193 证券简称：仁度生物 公告编号：2025-049 上海仁度生物科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 17 日 （二） 股东大会召开的地点：上海市浦东新区瑞庆路 528 号 15 幢公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 24 | | --- | --- | | 普通股股东人数 | 24 | | 2、出席会议的股东所持有的表决权数量 | 17,246,554 | | 普通股股东所持有表决权数量 | 17,246,554 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 44.4746 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 44.4746 | ...

R YE UNE BE A PT YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海仁度生物科技股份有限公司 北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 2025年第一次临时股东大会的 法律意见书 嘉源(2025)-04-835 北京市嘉源律师事务所(以下简称"本所")接受上海仁度生物科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《上海仁度生物科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司 2025年第一次临时股东大会(以下简称"本次 股东大会"）进行见证,并依法 ...

Core Points - Shanghai Rendu Biotechnology Co., Ltd. announced a change in its continuous supervision sponsor representative due to the work relocation of the original representative [2] - China International Capital Corporation (CICC) is the sponsor for the company's initial public offering (IPO) and listing on the Sci-Tech Innovation Board, with the continuous supervision period lasting until December 31, 2025 [2] - Yang Wei has been appointed as the new sponsor representative to ensure the orderly continuation of supervision work [2]